N-(indolecarbonyl)piperazine derivatives
CA 2383779 C · Owner: Seyfried, Christoph · Inventors: Greiner, Hartmut; Harting, Jurgen; Bartoszyk, Gerd
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds of the formula I, (see formula I) in which R1, R2, R4 and R5 have the meanings indicated in Claim 1, are potent 5-HT2A antagonists and are suitable for the treatment of psychoses schizophrenia, depression, neurological disorders memory disorders, Parkinson's disease, amyotrophic lateral sclerosis Alzheimer's disease, Huntington's disease eating , disorders such as bulimia, nervous anorexia premenstrual syndrome and/or for positively affecting compulsive behaviour (obsessive-compulsive disorder OCD).
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 7, 2000 and granted March 29, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 7, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 7, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.